Stay updated with breaking news from Philippe Barth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ROCKLAND, Mass.--(BUSINESS WIRE)--Jan 22, 2024--
Merck a leading science and technology company today announced new realworld data that continue to reinforce the JAVELIN Bladder regimen of firstline platinumbased chemotherapy followed by BAVENCIO avelumab maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma UC who do not progress on firstline chemotherapy.
Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless
Investegate announcements from Ipsen Pharma, Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
EverImmune says the first patient has been treated in its phase I clinical trial evaluating Oncobax AK in lung and kidney cancer patients.